Medidata Solutions upgraded to Buy from Neutral at B. Riley B. Riley upgraded Medidata Solutions to Buy citing yesterday's pullback in shares. The firm lowered its price target for shares to $49 from $53.
News For MDSO From The Last 14 Days
Check below for free stories on MDSO the last two weeks.
Medidata can obtain major new platform customers, says Stifel Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.